Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Aritinercept

Other · developed by Aurinia Pharmaceuticals

Phase 1/2 Most advanced trial

AUPH Developer

1 Registered trials

What is Aritinercept?

Aritinercept is an investigational drug studied in Myasthenia Gravis, Generalized.

At a glance

Drug type: Other
Therapy area: Oncology
Developer: Aurinia Pharmaceuticals Inc. (AUPH)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: 7L6F3P97K5

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07596901	Phase 1/2	Myasthenia Gravis, Generalized	Recruiting	AUPH

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Myasthenia Gravis, Generalized

More from Aurinia Pharmaceuticals

Voclosporin FDA approved VOS Phase 2/3

Sources

ClinicalTrials.gov NCT07596901

Updated Oct 3, 2026. Something wrong or missing? Report it on the AUPH page.

Follow AUPH, the company behind Aritinercept

See AUPH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AUPH catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z